July 24, 2025 4:41pm

As I had written, “When I see these record) highs, I say BYE especially with earnings on July’s next week’s tail end”. “Uncle algo and his electronic trading dwarfs” are in the house!

Whack-a-mole stock, Harvard Apparatus RT (OTCQB: HRGN) dives -$0.20 or -12.9% to $1.35 with only 200 shares traded. A question, D. Phone (with its overseer, MSS China’s secret security service) and its sub, Dixintong Technology Group from Beijing, China can’t find a “vehicle” to drop any more $’s to shore-up their lack of cash and runway <52-week range $0.935 to $5.90>? What happened to the reverse split and why replace it with an immediate private placement? Remember DST Capital subsidizes OTCQB: HRGN, run by Hong Yu. President of HRGN, Mrs. Bin (Zhao) from Weston, Mass and funded by her husband Lui Dong Hai, chairman of Dixintong Technology Group (D. Phone) in China

Never above you. Never below you. Always beside you … I say what others won’t, so you can do what others can’t!

Never leave an investor uninformed! 

 

My perspective is retail investors should roll-the-dice with econ readings until earnings season kicks-in and momentum wains in the cell and gene therapy sector. NO all ins as historically “our” universe slips and slides as the “season’ resumes; so, hang-in with those with solid partners, lengthened runways and solid cash positions leveraged by solid/stable management teams!

 

Thursday’s RegMed Investors’ (RMi) pre-open: I’m worried … https://www.regmedinvestors.com/articles/14011   

Wednesday night’s RegMed Investors (RMi) Closing Bell: Show me the money, as the sector upside slurps … https://www.regmedinvestors.com/articles/14010

RegMed Investors (RMi) Research Note: Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

 

Thursday: The Dow closed DOWN -316.20 points or -0.70%, the S&P closed UP +4.44 points or +0.07% while the Nasdaq closed UP +37.94 points or +0.18%

  • Theme of the session, progress on trade talks

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  •  Layoffs at U.S. companies remained low last week; jobless claims totaled a seasonally adjusted 217,000 for the week ending July 19, down 4,000 from the prior period and short of the consensus estimate for 227,000. Continuing claims, which run a week behind, also showed little change, up 4,000 to 1.955 million.

Thursday’s advance/decline line opened negative with 14 incliners, 16 decliners and 5 flats ending with a negative close of 7 incliners, 25 decliners and 3 flats         

Metrics:  Thursday, the IBB was up +0.02%, the XBI was down -0.73% while the VIX was up +0.16 points or +1.04% at 15.53

 

Q3 – 7/25 – 1 market holiday, 12 positive and 5 negative closes

Q2/25:

  • June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Thursday Closing UP (7 of 7) 

  • Alnylam Pharmaceuticals ALNY +$2.36),
  • Mesoblast (MESO +$0.89 after Wednesday’s +$1.01, Tuesday’s +$0.43 after Monday’s -$0.97),
  • Lenz Therapeutics (LENZ -$0.35),
  • Sangamo Therapeutics (SGMO +$0.0522 after Wednesday’s -$0.0148),
  • Regenxbio (RGNX +$0.04),
  • Voyager Therapeutics (VYGR +$0.03),
  • Verve Therapeutics (VERV +$0.03) – with expiration of tender offer

Flat (3)

  • bluebird bio (BLUE) P/E acquired
  • Blueprint Medicine (BPMC) acquired by SNY
  • Homology Medicine (FIXX)

Thursday’s Closing DOWN (10 of 25): 

  • CRISPR Therapeutics (CRSP -$2.08 after Wednesday’s +$2.21 after Tuesday’s +$0.60 after Monday’s +$0.20),
  • Intellia Therapeutics (NTLA -$1.46 after Wednesday’s +$0.75 after Tuesday’s +$0.86 after Monday’s +$0.57),
  • Beam Therapeutics (BEAM -$1.21 after Wednesday’s +$0.62 after Tuesday’s +$0.51 after Monday’s +$0.28),
  • Ultragenyx Pharmaceuticals (RARE -$0.71 after Wednesday’s +$1.57),
  • Moderna (MRNA -$0.66 after Wednesday’s +$1.94, Tuesday’s +$1.76 after Monday’s -$0.29)
  • Vericel (VCEL -$0.63 after Wednesday’s +$2.37, Tuesday’s +$2.52 and Monday’s +$0.12),
  • Cellectis SA (CLLS -$0.33),
  • Prime Medicine (PRME -$0.29),
  • AxoGen (AXGN -$0.25 after Wednesday’s +$0.92, Tuesday’s +$0.93 after Monday’s +$0.33),
  • Ionis Pharmaceuticals (IONS -$0.23)

 

 

The BOTTOM LINE: Cell and gene therapy sector equities pooped as …

  • US stocks traded mixed on Thursday, as hopes for a US-EU trade deal kept fresh records in sight and assessed earnings
  • The EU and US are closing in on an agreement that would impose a 15% tariff for most imports from Europe, instead of the 30% threatened.
  • That rate is emerging as a potential new baseline for the "reciprocal" tariffs set to kick in on Aug. 1, going by Trump's comments late Wednesday. Previously, the president had imposed a 10% baseline rate on countries as part of his sweeping April tariffs. <Yahoo Finance>

The cell and gene therapy sector closed negative on Thursday following Wednesday (7/23), Tuesday and Monday’s positive closes …

  • After slipping last Friday (7/18) following a positive close on last Thursday and Wednesday having slid on Tuesday after Monday’s positive close
  • And popping on the previous Friday, Thursday and Wednesday continued the upside after Tuesday positive close and diving on Monday ….
  • After the previous, previous week’s pop on multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

 

Earnings are a’comin: 7/29, Tuesday = uniQure NV (QURE), 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS) and Moderna (MRNA), 8/5, Tuesday = AxoGen (AXGN)

 

As I also wrote, the “June Swoon” is over … however, July will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

July evolves: understand the “flow” …

  • 7/24 – Thursday closed negative with 7 positive, 25 negative and 3 flats
  • 7/23 – Wednesday closed positive with 30 positive, 1 negative and 4 flats
  • 7/22 – Tuesday closed positive with 19 positive, 10 negative and 6 flats
  • 7/21 – Monday closed positive with 17 positive, 14 negative and 4 flats

Last week:

  • 7/18 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 7/17 – Thursday closed positive with 17 positive, 14 negative and 4 flats
  • 7/16 - Wednesday closed positive with 24 positive, 5 negative and 6 flats
  • 7/15 – Tuesday closed negative with 3 positive, 29 negative and 3 flats
  • 7/14 - Monday closed positive with 20 positive, 11 negative and 4 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Thursday: Alnylam Pharmaceuticals (ALNY), Mesoblast (MESO) and Lenz Pharmaceuticals (LENZ)
  • Wednesday: Vericel (VCEL), CRISPR Therapeutics (CRSP) and Moderna (MRNA)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Moderna (MRNA)
  • Monday: CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY) and Intellia Therapeutics (NTLA)

The worst three (3) in the session: 

  • Thursday: CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and Beam Therapeutics (BEAM)
  • Wednesday: Agenus AGEN)
  • Tuesday: Lenz Pharmaceuticals (LENZ), Precigen (PGEN) and uniQure NV (QURE)
  • Monday: Mesoblast (MESO), Vericel (VCEL) and uniQure NV (QURE)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.